Free shipping on all orders over $ 500

 About 25 results found for searched term "Notch" (0.039 seconds)

Cat.No.  Name Information
M2015 RO4929097 RO4929097 is a potent and selective inhibitor of γ-secretase and as a result is able to inhibit Notch pathway signaling.
M2703 FLI-06 FLI-06 is a novel inhibitor of Notch signaling with EC50 of 2.3 μM.
M2827 LY3039478 LY3039478 (Crenigacestat) is a novel and orally active Notch and γ-secretase inhibitor, with an IC50 of 1 nM in most of the tumor cell lines tested.
M2828 LY900009 LY900009 is a potent, first-in-class Notch inhibitor with IC50 of 0.27 nM.
M3523 YO-01027 YO-01027 (Dibenzazepine, DBZ) is a dipeptidic γ-secretase inhibitor with IC50 of 2.6 nM and 2.9 nM for APPL and Notch cleavage, respectively.
M3619 Begacestat Begacestat selectively inhibits cleavage of amyloid precursor protein (APP) over Notch. Lowers levels of Aβ42 and Aβ40 (EC50 values are 12.4 and 14.8 nM respectively in cells expressing human recombinant APP).
M4553 Tangeretin Tangeretin is a flavonoid from citrus fruit peels, and is also selected as a Notch-1 inhibitor, which plays an important role in anti-inflammatory responses and neuroprotective effects in several disease models.
M6699 EDTA EDTA is a chelating agent. EDTA can activate NOTCH1 signaling.
M7667 BMS-906024 BMS-906024 is a γ-secretase inhibitor and pan-Notch inhibitor with IC50 values of 1.6 nM, 0.7 nM, 3.4 nM, and 2.9 nM for Notch1, 2, 3, and 4 receptors, respectively. BMS-906024 has antineoplastic activity.
M8679 IMR-1 IMR-1 is a cell penetrant and potent inhibitor of Notch transcriptional activation complex that disrupted the recruitment of Mastermind-like 1 (Maml1) to the Notch transcriptional activation complex on chromatin.
M9505 Compound E Compound E is a cell-permeable, potent, selective inhibitor of γ-secretase and Notch processing.
M10088 NVS-ZP7-4 NVS-ZP7-4 is a potent ZIP7 Inhibitor, which inhibits Notch signaling with IC50 of 0.13 uM in HES-Luc reporter gene assays, selectively induces apoptosis and ER stress.
M10373 CB-103 CB-103 is a first-in-class, orally active inhibitor of the Notch transcription activation complex. CB-103 inhibits Notch signaling in primary human T cell acute lymphoblastic leukemia and other Notch-dependent human tumor cell lines, and concomitantly induces cell cycle arrest and apoptosis.
M10798 BMS-983970 BMS-983970 is an oral Notch inhibitor with antitumor activity.
M11280 Z-Ile-Leu-aldehyde Z-ile-leu-aldehyde (Z-IL-Cho) is a potent and competitive peptide-aldehyde inhibitor of gamma-secretase and Notch.
M14569 Bruceine D Bruceine D is a Notch inhibitor with anti-cancer activity and induces apoptosis in several human cancer cells.
M14571 IMR-1A IMR-1A, a acid metabolite of IMR-1, is a Notch inhibitor with an IC50 of 0.5 μM. IMR-1A has a 50-fold increase in potency with respect to IMR-1. IMR-1 can metabolize in vivo to IMR-1A.
M14572 Jagged-1 (188-204) (TFA) Jagged-1 (188-204) TFA is a fragment of the Jagged-1 (JAG-1) protein. JAG-1 is a Notch ligand highly expressed in cultured and primary multiple myeloma (MM) cells. JAG-1 induces maturation of monocyte-derived human dendritic cells.
M14574 Notch inhibitor 1 Notch inhibitor 1 is a potent Notch inhibitor, with IC50s of 7.8 and 8.5 nM for Notch 1 and Notch 3, respectively. Used in the research of cancer.
M14575 RBPJ Inhibitor-1 RBPJ Inhibitor-1 (RIN1), the first RBPJ inhibitor, blocks the functional interaction of RBPJ with SHARP. RBPJ Inhibitor-1 (RIN1) inhibits NOTCH-dependent tumor cell proliferation.
M14583 E 2012 E 2012 is a potent gamma (γ) secretase modulator without affecting Notch processing.
M24588 Demcizumab Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models.
M24627 Tarextumab Tarextumab (OMP-59R5) is an anti-Notch2/3 fully human IgG2 monoclonal antibody. Tarextumab shows anti-tumor activity.
M24681 Brontictuzumab Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma.
M25550 ASR-490  ASR-490 reduces the viability of HCT116 and SW620 cells by downregulating Notch1 signaling. ASR-490 overcomes Notch1 overexpression and inhibits the growth of HCT/Notch1 transfectants. ASR-490 inhibits the tumor growth in control (pCMV/HCT116) and Notch1/HCT116 in xenotransplanted mice.

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.